CANCER:

GastroEsophageal Cancer

Related cancers:

‹

Gastric Cancer (524)

Gastroesophageal Junction Adenocarcinoma (121)

Gastric Adenocarcinoma (29)

Gastric Cancer (524)

Gastroesophageal Junction Adenocarcinoma (121)

Gastric Adenocarcinoma (29)

›

HER-2 positive HER-2 positive	GastroEsophageal Cancer GastroEsophageal Cancer	HER-2 positive HER-2 positive	GastroEsophageal Cancer GastroEsophageal Cancer	trastuzumab Sensitive: A2 - Guideline	trastuzumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	PD-L1 overexpression PD-L1 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	PD1 inhibitor Sensitive: B - Late Trials	PD1 inhibitor Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	PD-L1 overexpression PD-L1 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	PD-L1 inhibitor Sensitive: B - Late Trials	PD-L1 inhibitor Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	GastroEsophageal Cancer GastroEsophageal Cancer	PD-L1 expression PD-L1 expression	GastroEsophageal Cancer GastroEsophageal Cancer	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
HER-2 positive HER-2 positive	GastroEsophageal Cancer GastroEsophageal Cancer	HER-2 positive HER-2 positive	GastroEsophageal Cancer GastroEsophageal Cancer	pembrolizumab + trastuzumab Sensitive: C1 - Off-label	pembrolizumab + trastuzumab Sensitive: C1 - Off-label
HER-2 positive HER-2 positive	GastroEsophageal Cancer GastroEsophageal Cancer	HER-2 positive HER-2 positive	GastroEsophageal Cancer GastroEsophageal Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria	pembrolizumab Sensitive: C2 – Inclusion Criteria
TP53 mutation TP53 mutation	GastroEsophageal Cancer GastroEsophageal Cancer	TP53 mutation TP53 mutation	GastroEsophageal Cancer GastroEsophageal Cancer	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
TET1 mutation TET1 mutation	GastroEsophageal Cancer GastroEsophageal Cancer	TET1 mutation TET1 mutation	GastroEsophageal Cancer GastroEsophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
HER-2 expression HER-2 expression	GastroEsophageal Cancer GastroEsophageal Cancer	HER-2 expression HER-2 expression	GastroEsophageal Cancer GastroEsophageal Cancer	ZW25 Sensitive: C3 – Early Trials	ZW25 Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	GastroEsophageal Cancer GastroEsophageal Cancer	PD-L1 expression PD-L1 expression	GastroEsophageal Cancer GastroEsophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
HER-2 overexpression HER-2 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	HER-2 overexpression HER-2 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	disitamab vedotin Sensitive: C3 – Early Trials	disitamab vedotin Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	GastroEsophageal Cancer GastroEsophageal Cancer	PD-L1 expression PD-L1 expression	GastroEsophageal Cancer GastroEsophageal Cancer	tislelizumab Sensitive: C3 – Early Trials	tislelizumab Sensitive: C3 – Early Trials
FGFR2 amplification FGFR2 amplification	GastroEsophageal Cancer GastroEsophageal Cancer	FGFR2 amplification FGFR2 amplification	GastroEsophageal Cancer GastroEsophageal Cancer	ABSK-091 Sensitive: C3 – Early Trials	ABSK-091 Sensitive: C3 – Early Trials
MET amplification MET amplification	GastroEsophageal Cancer GastroEsophageal Cancer	MET amplification MET amplification	GastroEsophageal Cancer GastroEsophageal Cancer	crizotinib Sensitive: C3 – Early Trials	crizotinib Sensitive: C3 – Early Trials
TGFB1 elevation TGFB1 elevation	GastroEsophageal Cancer GastroEsophageal Cancer	TGFB1 elevation TGFB1 elevation	GastroEsophageal Cancer GastroEsophageal Cancer	M7824 Sensitive: C3 – Early Trials	M7824 Sensitive: C3 – Early Trials
HER-2 overexpression HER-2 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	HER-2 overexpression HER-2 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	ZW25 Sensitive: C3 – Early Trials	ZW25 Sensitive: C3 – Early Trials
MET amplification MET amplification	GastroEsophageal Cancer GastroEsophageal Cancer	MET amplification MET amplification	GastroEsophageal Cancer GastroEsophageal Cancer	afatinib Resistant: C3 – Early Trials	afatinib Resistant: C3 – Early Trials
EGFR amplification + ERBB2 amplification EGFR amplification + ERBB2 amplification	GastroEsophageal Cancer GastroEsophageal Cancer	EGFR amplification + ERBB2 amplification EGFR amplification + ERBB2 amplification	GastroEsophageal Cancer GastroEsophageal Cancer	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
CFB overexpression CFB overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	CFB overexpression CFB overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	sunitinib Sensitive: C3 – Early Trials	sunitinib Sensitive: C3 – Early Trials
VEGFC-H VEGFC-H	GastroEsophageal Cancer GastroEsophageal Cancer	VEGFC-H VEGFC-H	GastroEsophageal Cancer GastroEsophageal Cancer	sunitinib Sensitive: C3 – Early Trials	sunitinib Sensitive: C3 – Early Trials
HER-2 positive HER-2 positive	GastroEsophageal Cancer GastroEsophageal Cancer	HER-2 positive HER-2 positive	GastroEsophageal Cancer GastroEsophageal Cancer	pembrolizumab + margetuximab Sensitive: C3 – Early Trials	pembrolizumab + margetuximab Sensitive: C3 – Early Trials
POLE mutation POLE mutation	GastroEsophageal Cancer GastroEsophageal Cancer	POLE mutation POLE mutation	GastroEsophageal Cancer GastroEsophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
POLD1 mutation POLD1 mutation	GastroEsophageal Cancer GastroEsophageal Cancer	POLD1 mutation POLD1 mutation	GastroEsophageal Cancer GastroEsophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	GastroEsophageal Cancer GastroEsophageal Cancer	PD-L1 expression PD-L1 expression	GastroEsophageal Cancer GastroEsophageal Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	GastroEsophageal Cancer GastroEsophageal Cancer	PD-L1 expression PD-L1 expression	GastroEsophageal Cancer GastroEsophageal Cancer	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
HER-2 positive + HER-2 amplification HER-2 positive + HER-2 amplification	GastroEsophageal Cancer GastroEsophageal Cancer	HER-2 positive + HER-2 amplification HER-2 positive + HER-2 amplification	GastroEsophageal Cancer GastroEsophageal Cancer	trastuzumab Sensitive: C3 – Early Trials	trastuzumab Sensitive: C3 – Early Trials
CTAG1A expression CTAG1A expression	GastroEsophageal Cancer GastroEsophageal Cancer	CTAG1A expression CTAG1A expression	GastroEsophageal Cancer GastroEsophageal Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	GastroEsophageal Cancer GastroEsophageal Cancer	HER-2 mutation HER-2 mutation	GastroEsophageal Cancer GastroEsophageal Cancer	dasatinib Sensitive: D – Preclinical	dasatinib Sensitive: D – Preclinical
HER-2 mutation HER-2 mutation	GastroEsophageal Cancer GastroEsophageal Cancer	HER-2 mutation HER-2 mutation	GastroEsophageal Cancer GastroEsophageal Cancer	neratinib Sensitive: D – Preclinical	neratinib Sensitive: D – Preclinical
HER-2 mutation HER-2 mutation	GastroEsophageal Cancer GastroEsophageal Cancer	HER-2 mutation HER-2 mutation	GastroEsophageal Cancer GastroEsophageal Cancer	dasatinib + neratinib Sensitive: D – Preclinical	dasatinib + neratinib Sensitive: D – Preclinical
BCL2 overexpression + MCL1 overexpression BCL2 overexpression + MCL1 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	BCL2 overexpression + MCL1 overexpression BCL2 overexpression + MCL1 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	AT 101 Sensitive: D – Preclinical	AT 101 Sensitive: D – Preclinical

GastroEsophageal Cancer

Associations(31)

Associations
(31)